Keflex Pulsys: Phase III start

MBRK (formerly Advancis Pharmaceutical Corp.) will begin a double-blind, non-inferiority Phase III trial in >=600 patients to compare 1,200 mg Keflex PULSYS once daily vs. 250 mg of Keflex cephalexin...